STOCK TITAN

DURECT SEC Filings

DRRX Nasdaq

Welcome to our dedicated page for DURECT SEC filings (Ticker: DRRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The DURECT Corporation (DRRX) SEC filings page on Stock Titan provides access to historical regulatory documents filed by this former Nasdaq-listed biopharmaceutical company. These filings trace DURECT’s evolution as a late-stage developer of epigenetic therapies, its financial reporting as a public issuer, and the steps that led to its acquisition by a subsidiary of Bausch Health Americas, Inc. and subsequent delisting.

For users analyzing DURECT’s business, earlier periodic reports and current reports on Form 8-K describe the company’s focus on larsucosterol, an investigational epigenetic modulator in clinical development for alcohol-associated hepatitis (AH), and disclose that the U.S. Food and Drug Administration granted larsucosterol Fast Track and Breakthrough Therapy designations for this indication. Other filings reference the company’s FDA-approved non-opioid analgesic POSIMIR, based on its SABER platform technology, and the sale of the ALZET osmotic pump product line.

Later filings are particularly important for understanding DRRX’s trading and registration status. A series of Forms 8-K in 2025 describe the Agreement and Plan of Merger with Bausch Health Americas, Inc., the commencement and terms of the tender offer for all outstanding DURECT shares, amendments to the merger agreement, and the completion of the merger on September 11, 2025. A Form 25 filed by The Nasdaq Stock Market LLC on that date documents the removal of DURECT’s common stock from listing on Nasdaq. Subsequently, a Form 15 filed on September 22, 2025 certifies the termination of registration of the common stock under Section 12(g) of the Exchange Act and the suspension of DURECT’s duty to file reports under Sections 13 and 15(d).

On Stock Titan, these filings are accompanied by AI-generated highlights that help explain key sections, such as change-of-control terms in merger-related 8-Ks, delisting notices, and the implications of Form 15 deregistration. Users can quickly identify documents related to corporate transactions, historical financial condition, and the regulatory history of larsucosterol and POSIMIR, while still having direct access to the full text as filed with the SEC.

Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

James E. Brown, who is listed as President & CEO and a director of DURECT Corp (DRRX), reported a transaction dated 09/11/2025 involving the disposition of a stock option covering 103,077 shares with a $1.30 exercise/conversion price.

The filing explains this activity occurred in connection with a Merger Agreement and a related tender offer by Bausch Health Americas, Inc. Options with exercise prices below the cash consideration were accelerated and, if exercised before the merger became effective, the resulting shares were treated the same as other shares in the tender offer. Options with exercise prices equal to or above the cash consideration that remained unexercised at the effective time were canceled and former holders are eligible for cash retention bonuses tied to net sales milestones under a board-approved retention plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Insider grant and purchase reported: Director Gail M. Farfel reported a transaction in DURECT CORP (DRRX) showing acquisition of both common stock and a stock option on 09/10/2025. The filing shows 5,500 shares of common stock acquired at $1.22 per share, bringing Ms. Farfel's direct holdings to 15,500 shares. The filing also discloses a stock option granted on the same date with a $1.22 exercise price covering 5,500 underlying shares; the option becomes fully exercisable one day before the first anniversary of grant and expires on 09/25/2034. The Form 4 is signed 09/11/2025 and identifies Ms. Farfel as a director filing individually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

James E. Brown, President & CEO and a director of DURECT Corporation (DRRX), reported two option grants on 09/09/2025 and 09/10/2025. Each grant is reported with transaction code M (award of options) for 131,923 and 130,000 stock options respectively, both with an exercise price of $1.30 and an expiration date of 10/14/2034. The filings show post-transaction direct beneficial ownership of 415,335 shares after the first grant and 545,335 shares after the second grant, plus 8,000 shares held indirectly by the Brown Family Trust dated 5/10/2006. The options vest in installments of one-sixteenth every three months following the grant, subject to continuous service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Judith J. Robertson, a director of DURECT Corp (DRRX), received an equity award consisting of a stock option covering 5,500 shares exercisable at $1.22 per share. The option grant date and associated transaction is reported as 09/10/2025. The option vests 100% on the day before the first anniversary of the grant, conditioned on continued service through the vesting date. After the reported grant and related exercise rights, Ms. Robertson beneficially owns 41,113 shares of common stock and holds options covering an additional 5,500 shares that expire on 09/25/2034. The disclosure is a Form 4 reporting a director-level equity award and resulting beneficial ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Peter S. Garcia, a director of DURECT Corporation (DRRX), received an option grant on 09/09/2025 covering 5,500 shares with an exercise price of $1.22. The Form 4 shows the option is a stock option exercisable for 5,500 shares of common stock and that the reporting person owned 12,500 shares of common stock following the transaction. The disclosure states the option vests 100% on the day before the first anniversary of the grant date, subject to continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Gail J. Maderis, a director of DURECT Corporation (DRRX), reported option and stock activity on 09/09/2025. The filing shows the grant of a stock option to purchase 5,500 shares at an exercise price of $1.22, with the option exercisable after vesting and an expiration date of 09/25/2034. The option vests 100% on the day before the first anniversary of the grant, subject to continued service. The report also shows acquisition of 5,500 shares of common stock (direct) and indirect beneficial ownership of 20,000 shares held by the Gail J. Maderis Revocable Trust dated 04-08-2013, for reported holdings of 5,500 direct and 20,000 indirect shares following the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Durect Corporation filed an S-8 registration statement listing multiple prior S-8 registrations and the number of common shares registered under various employee plans across years. The filing documents repeated registrations of shares for the 2000 Stock Plan and the Employee Stock Purchase Plan, including large blocks such as 18,000,000 shares registered on August 5, 2022 and 7,500,000 on August 2, 2018, plus a 1-for-10 reverse stock split effected on December 5, 2022. Recent registrations include 40,000 shares (post-split) for the ESPP on August 10, 2023 and 2,000,000 shares (post-split) for the 2000 Stock Plan on November 14, 2024. The document is signed by the CFO, confirming the administrative update to registered employee equity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Durect Corporation (DRRX) filed an S-8 post-effective amendment registering shares for employee benefit plans. The filing lists multiple prior S-8 registration statements and the specific share amounts registered under various plans, including recent entries of 40,000 shares under the Employee Stock Purchase Plan and 2,000,000 shares under the 2000 Stock Plan (each number shown after the 1-for-10 reverse stock split). The document also notes the 1-for-10 reverse stock split effected on December 5, 2022, and is signed by CFO Timothy M. Papp.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Durect Corporation filed an S-8 prospectus in connection with multiple prior S-8 registrations and to register 2,000,000 shares of Common Stock under its 2000 Stock Plan (amounts shown are after the 1-for-10 reverse stock split effected on December 5, 2022). The filing lists a series of historical S-8 registrations dating back to October 5, 2000, covering employee option plans, an employee stock purchase plan and directors' option plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of DURECT (DRRX)?

The current stock price of DURECT (DRRX) is $1.91 as of September 11, 2025.

What is the market cap of DURECT (DRRX)?

The market cap of DURECT (DRRX) is approximately 59.3M.
DURECT

Nasdaq:DRRX

DRRX Rankings

DRRX Stock Data

59.31M
27.26M
12.67%
23.58%
1.11%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CUPERTINO

DRRX RSS Feed